Key result
LOX-1 promotes efferocytosis but restricts phagocytosis and inflammatory responses in alveolar macrophages.
LOX-1 acts as an immunoregulatory receptor in the lungs during infection by promoting alveolar macrophage efferocytosis and modulating inflammatory factor expression.
Introduction Pneumonia is a worldwide public health concern, necessitating improved understanding of host response to lung pathogens. We recently reported that lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) limits inflammatory injury, partially mediated by alveolar macrophages (AMs). While oxidized low-density lipoprotein (oxLDL), the primary ligand for LOX-1, elicits inflammation in extrapulmonary macrophages, it is unknown whether oxLDL or other LOX-1 ligands alter AM function, thereby regulating the host response to lung infection. Methods Primary AMs or MH-S cells were cultured with oxLDL or apoptotic cells (± anti-LOX-1 or control IgG) to determine primary outcomes and, subsequently, LPS or GFP-labeled E. coli to determine secondary outcomes. WT mice were treated intranasally with oxLDL (± anti-LOX-1 or control IgG) for 24H or after one week, infected with E. coli. WT mice were treated intratracheally (± anti-LOX-1 or control IgG) with apoptotic cells or GFP-labeled E. coli to determine the impact of LOX-1 on efferocytosis or phagocytosis, respectively. Outcomes were measured by live-cell imaging, flow cytometry, RT-qPCR or ELISA. Results Earlier work showed that LOX-1 limits injury and inflammation during pneumonia, potentially via AMs. Here, we found that LOX-1 promotes efferocytosis, while limiting phagocytosis in AMs. Moreover, pre-stimulation of AMs with oxLDL reduced iNOS and IL-1B expression in response to LPS or E. coli, while promoting IL-6 and CXCL2 expression. Arginase-1, while suppressed in AMs, was more highly expressed in neutrophils following administration of oxLDL and infection with E. coli, independent of LOX-1. Conclusion LOX-1 has emerged as a unique immunoregulatory receptor in the lungs during infection. Our data show that this likely occurs through increased AM efferocytosis and oxLDL-dependent regulation of inflammatory factors, such as iNOS. Future studies will further interrogate LOX-1-dependent and independent mechanisms of protection against lung injury. Funding Source NHLBI Topic Categories Microbial, Parasitic, and Fungal Immunology (MPF)
No takes yet. Share an insight, caveat, or question.
Korkmaz et al. (2026) studied Pneumonia. oxLDL and anti-LOX-1 vs. control IgG was evaluated on Efferocytosis, phagocytosis, and inflammatory factor expression. LOX-1 promotes efferocytosis and limits phagocytosis in alveolar macrophages, while oxLDL pre-stimulation reduces iNOS and IL-1B expression in response to infection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: